Plant Name: Lobelia chinensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD4; | |
| TSHR; NPSR1; CXCR1; | |
| PLA2G1B; TDP1; RECQL; PKM; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; | |
| ACHE; | |
| CHRNA7; | |
| CFTR; | |
| TRPA1; | |
| PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; SYK; NEK2; FLT3; SRC; IGF1R; AURKB; GSK3B; KDR; CDK1; PIM1; NUAK1; ALK; PTK2; AXL; NEK6; CDK6; | |
| CA12; CA7; CA5A; CA3; CA14; CA5B; CA1; CA9; CA13; CA4; CA6; CA2; | |
| AR; | |
| PPARA; PPARD; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| MMP13; MMP12; MMP3; MMP2; MMP9; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; NPC1; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nicotinic acetylcholine receptor | CHRNA7 | Neuronal acetylcholine receptor protein alpha-7 subunit | P36544 | CHEMBL2492 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.973E-13 | 1.377E-10 | AR, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, PARP1, PPARA, PPARD, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.087E-13 | 1.400E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.631E-11 | 4.129E-09 | AURKB, CA2, CA7, CD38, CDK6, CFTR, HIF1A, KDR, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2, TRPA1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.164E-11 | 7.561E-09 | ABCG2, ACHE, AKT1, ALK, APP, CAMK2B, CD38, CHRNA7, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, IGF1R, KDR, L3MBTL1, MAPT, MET, MMP9, NFKB1, PARP1, PKM, PTGS2, PYGL, SMN1, SMN2, STAT6, TP53, TRPA1, TTR, USP2, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.194E-11 | 7.561E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.673E-11 | 2.065E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.333E-10 | 2.764E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4, NOX4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.212E-10 | 7.975E-08 | AURKB, CA2, CA7, CFTR, HIF1A, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.424E-09 | 2.501E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.967E-08 | 3.940E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC, SYK, TNKS |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 3.380E-08 | 4.407E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1, SYK |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.432E-08 | 1.075E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.891E-07 | 1.980E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.676E-07 | 2.636E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1, TNKS |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.420E-07 | 4.113E-05 | CYP1A2, CYP2A6, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.420E-07 | 4.113E-05 | CYP1A2, CYP2C8, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.772E-07 | 6.033E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.326E-06 | 1.094E-04 | AKT1, ALOX12, APP, AR, AXL, CA2, CAMK2B, CDK1, CDK6, CHRNA7, CYP1B1, ESR1, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, PIK3R1, PIM1, PPARD, PTGS2, PTK2, SRC, STAT6, SYK, THPO, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.597E-06 | 1.293E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.686E-06 | 1.350E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.910E-06 | 1.496E-04 | AKT1, HIF1A, LMNA, PPARD, PTGS2, SRC, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.080E-06 | 1.612E-04 | AURKB, NEK2, TNKS, TNKS2 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.171E-06 | 1.677E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.336E-06 | 2.422E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.358E-06 | 2.422E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.358E-06 | 2.422E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.391E-06 | 3.064E-04 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 4.846E-06 | 3.339E-04 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, PARP1, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.853E-06 | 3.911E-04 | CYP1A1, CYP2A6, CYP2D6 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 5.998E-06 | 3.994E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.334E-06 | 4.154E-04 | IGF1R, KDR, PTK2, SRC, SYK |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 6.599E-06 | 4.289E-04 | AKT1, ALOX12, ALOX15, AR, CDK6, CYP19A1, DAPK1, ESR1, ESR2, GSK3B, HIF1A, IGF1R, LMNA, MET, MMP12, MMP9, NFKB1, PPARA, PPARD, PTGS2, SRC, STAT6, XDH |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 8.688E-06 | 5.329E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 8.688E-06 | 5.329E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.059E-05 | 6.355E-04 | AKR1B1, AKT1, ALOX12, ALOX15, ALOX5, APP, AR, AURKB, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.068E-05 | 6.388E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.130E-05 | 6.668E-04 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.469E-05 | 8.462E-04 | PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.469E-05 | 8.462E-04 | APP, GSK3B, IGF1R, PARP1 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.572E-05 | 8.987E-04 | ALK, CDK1, CHRNA7, DRD4, PKN1, PLA2G1B, SYK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.230E-25 | 4.855E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.842E-05 | 1.042E-03 | APP, CDK1, PARP1, PIK3R1, PTGS2, TLR2 |
| BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.960E-05 | 1.086E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.982E-05 | 1.090E-03 | CA2, CA7, CFTR |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.213E-05 | 1.205E-03 | CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC, TRPA1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.309E-05 | 1.250E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.334E-05 | 1.261E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 2.648E-05 | 1.393E-03 | AURKB, CYP2D6, GSK3B, MET, NEK2, PPARA, TNKS |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.715E-05 | 1.421E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.946E-05 | 1.531E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.097E-05 | 1.579E-03 | ALOX12, ALOX15 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.104E-05 | 1.579E-03 | AXL, CSNK2A1, DRD4, ESR1, GSK3B, PPARA, SRC, TP53, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 3.097E-05 | 1.579E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.097E-05 | 1.579E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.097E-05 | 1.579E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 3.149E-05 | 1.598E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.649E-05 | 1.818E-03 | DRD4, FABP3, PLA2G1B, PPARA, PPARD |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 3.766E-05 | 1.868E-03 | AURKB, NEK2, TNKS, TNKS2 |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 3.829E-05 | 1.895E-03 | AKT1, APP, AR, AXL, CA2, CAMK2B, HIF1A, KDR, MAPT, NFKB1, PARP1, PPARD, PTGS2, SYK, THPO, TLR2 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 3.922E-05 | 1.936E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.959E-05 | 1.950E-03 | APP, BACE1, CHRNA7, KDR, NPC1, PTGS2, SRC, STAT6, TLR2 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.373E-05 | 2.130E-03 | AKR1B1, AKT1, ALOX5, AR, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HIF1A, L3MBTL1, LMNA, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, POLB, PPARA, PPARD, RECQL, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.667E-05 | 2.264E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 4.743E-05 | 2.285E-03 | CA2, CD38, SRC, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 5.171E-05 | 2.459E-03 | MMP12, NFKB1, STAT6, SYK, TLR2 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 5.171E-05 | 2.459E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 5.295E-05 | 2.507E-03 | ESR1, NEK6, PPARA, TP53 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 5.893E-05 | 2.747E-03 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 5.916E-05 | 2.747E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 6.064E-05 | 2.809E-03 | APP, CA2, CA7, CHRNA7, DRD4, PTGS2 |
| BP | GO:0032502; developmental process | GO:0048638; regulation of developmental growth | 6.276E-05 | 2.895E-03 | AKT1, APP, AR, CDK1, MAPT, PIM1, PPARD, PTK2, TNKS2 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 6.578E-05 | 3.016E-03 | ABCG2, ACHE, AKT1, AR, AXL, CAMK2B, CHRNA7, FLT3, HIF1A, MAPT, NFKB1, PIK3R1, PPARD, PTGS2, PYGL, TLR2, TP53, TTR, XDH |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.708E-05 | 3.056E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 6.708E-05 | 3.056E-03 | AKR1B1, AKT1, MMP2, MMP9, PTGS2 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 8.076E-05 | 3.567E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 8.292E-05 | 3.647E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 8.576E-05 | 3.754E-03 | AKT1, FABP3, PTGS2, SRC, TLR2 |
| BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 8.585E-05 | 3.754E-03 | AKT1, LMNA, MAPT, MET, NEK2, PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 9.100E-05 | 3.931E-03 | AKR1B1, AKT1, AR, CFTR, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 9.258E-05 | 3.937E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 9.258E-05 | 3.937E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.258E-05 | 3.937E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 9.258E-05 | 3.937E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.258E-05 | 3.937E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.258E-05 | 3.937E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.258E-05 | 3.937E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 9.179E-05 | 3.937E-03 | AKT1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, HSD17B10, MAOA, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, SRC, TP53 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 9.392E-05 | 3.963E-03 | AKT1, ESR1, GSK3B, HIF1A, NEK6, PARP1, PIK3R1, PKN1, PTK2, SRC, SYK, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.056E-04 | 4.364E-03 | AKT1, HIF1A, KDR, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.092E-04 | 4.494E-03 | AKT1, CYP1B1, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.092E-04 | 4.494E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.154E-04 | 4.706E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.206E-04 | 4.888E-03 | ALOX15, APP, CHRNA7, KDR, NOX4, SRC, THPO |
| BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 1.259E-04 | 5.048E-03 | APP, PIK3R1, PTGS2, TLR2 |
| BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 1.359E-04 | 5.380E-03 | ALK, APP, AR, NFKB1, PLA2G1B, TLR2 |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.379E-04 | 5.441E-03 | ACHE, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, PIK3R1, PKM, PPARA, SRC, SYK, TLR2, TSHR |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.528E-04 | 5.956E-03 | APP, AR, CDK6, CYP1B1, FABP3, LMNA, NOX4, PKN1, PPARD, PTGS2, TLR2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 1.543E-04 | 5.980E-03 | APP, AURKB, GSK3B, MET, MMP9, PPARA, SRC |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.585E-04 | 6.120E-03 | CD38, PARP1, SRC, TNKS, TNKS2, TRPA1 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.650E-04 | 6.348E-03 | AXL, CYP1A1, CYP1A2, MPO, NFKB1, PPARD, PTGS2, SRC |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.710E-04 | 6.556E-03 | AKT1, ALOX15, AXL, DAPK1, FABP4, FLT3, GSK3B, HIF1A, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.845E-04 | 6.897E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.845E-04 | 6.897E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.845E-04 | 6.897E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.845E-04 | 6.897E-03 | ESR1, ESR2 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.847E-04 | 6.897E-03 | CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYP3A4, HSD17B2, NOX4, PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 1.934E-04 | 7.188E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.934E-04 | 7.188E-03 | AKT1, HIF1A, MMP9, PTGS2, SRC |
| CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 1.933E-04 | 7.188E-03 | AR, AURKB, CDK1, CSNK2A1, ESR1, PARP1, PPARD, STAT6, TNKS, TNKS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 2.101E-04 | 7.714E-03 | CA2, PTGS2, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.101E-04 | 7.714E-03 | CYP1A1, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0009986; cell surface | 2.270E-04 | 8.306E-03 | ACHE, APP, AXL, BACE1, CA4, CD38, CFTR, MET, PLA2G1B, TLR2, TSHR |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 2.283E-04 | 8.340E-03 | ALOX12, CHRNA7, CYP1B1, HIF1A, KDR, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.357E-04 | 8.597E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.775E-04 | 9.971E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.113E-19 | 2.031E-16 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.293E-17 | 6.780E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.980E-24 | 3.743E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.750E-12 | 4.488E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; TP53; MET; TLR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.347E-11 | 2.739E-09 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MET; TP53; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.472E-10 | 1.168E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.632E-09 | 3.641E-07 | APP; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.934E-08 | 8.898E-07 | GSK3B; SYK; PIK3R1; PTK2; NFKB1; IGF1R; CDK6; KDR; AKT1; PKN1; TP53; MET; TLR2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.237E-08 | 8.898E-07 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.423E-08 | 4.483E-07 | CYP2C8; CYP2A6; CHRNA7; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.728E-08 | 1.672E-06 | CDK6; SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.637E-08 | 7.119E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.329E-08 | 1.385E-06 | PKM; FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.214E-07 | 1.912E-06 | GSK3B; SRC; AKT1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.268E-07 | 6.418E-06 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.163E-07 | 6.048E-06 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.390E-07 | 7.351E-06 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.772E-07 | 6.418E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.620E-07 | 6.418E-06 | FABP4; AKT1; PIK3R1; PTGS2; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.254E-07 | 6.566E-06 | FLT3; PIM1; AKT1; PIK3R1; NFKB1; PPARD |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.511E-06 | 1.196E-05 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.089E-06 | 9.801E-06 | SRC; MMP2; AKT1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.707E-06 | 1.290E-05 | POLB; CDK6; PKM; SYK; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 9.403E-07 | 8.886E-06 | SRC; KDR; AKT1; PIK3R1; PTGS2; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.375E-06 | 1.181E-05 | CAMK2B; CDK6; AKT1; PIK3R1; TP53; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.502E-06 | 1.631E-05 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C8; CYP2A6; PKM; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; CD38; XDH |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.322E-06 | 1.567E-05 | CDK6; AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.546E-06 | 2.095E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; ESR1; HIF1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.480E-07 | 6.048E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.960E-06 | 1.372E-05 | CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.399E-05 | 7.555E-05 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.960E-06 | 1.372E-05 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.634E-06 | 4.372E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.736E-06 | 1.668E-05 | CYP2A6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.016E-05 | 1.058E-04 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.366E-05 | 1.552E-04 | ABCC1; CDK6; PIM1; CYP1B1; PTGS2; TP53; MMP9; MET; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.781E-05 | 1.383E-04 | GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.929E-05 | 1.384E-04 | MMP3; AKT1; PIK3R1; PTGS2; MMP9; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.283E-05 | 7.134E-05 | ALK; CDK6; AKT1; PIK3R1; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.782E-05 | 2.054E-04 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.027E-05 | 2.887E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.037E-04 | 4.084E-04 | CAMK2B; AKT1; PIK3R1; PPARA; CFTR; NFKB1; TSHR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.126E-04 | 4.342E-04 | PARP1; LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.877E-05 | 1.384E-04 | CDK6; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.482E-05 | 3.411E-04 | GSK3B; AKT1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.692E-05 | 2.054E-04 | GSK3B; SYK; AKT1; PIK3R1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.692E-05 | 2.054E-04 | CDK6; AKT1; PIK3R1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.670E-05 | 1.364E-04 | CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.685E-06 | 1.668E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.335E-04 | 7.882E-04 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.196E-04 | 7.545E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.907E-04 | 6.799E-04 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.568E-04 | 5.809E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.404E-04 | 1.129E-03 | CAMK2B; ACHE; CHRNA7; AKT1; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.196E-04 | 7.545E-04 | CAMK2B; PKM; AKT1; PYGL; PPARA |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.491E-04 | 5.634E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.127E-04 | 1.322E-03 | CAMK2B; SYK; SRC; AKT1; NFKB1; TLR2 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.511E-04 | 1.398E-03 | ALOX5; AKT1; PIK3R1; NFKB1; TLR2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.254E-04 | 1.551E-03 | SYK; SRC; AKT1; PIK3R1; PTGS1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.006E-03 | 2.755E-03 | SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.872E-04 | 1.485E-03 | ABCC1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.771E-04 | 1.939E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.371E-03 | 3.649E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.043E-03 | 2.816E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.674E-03 | 4.334E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.674E-03 | 4.334E-03 | CAMK2B; SRC; CD38; PIK3R1; PTGS2 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.780E-03 | 6.330E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.189E-03 | 5.238E-03 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 3.317E-03 | 7.464E-03 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.968E-03 | 4.830E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.480E-04 | 1.398E-03 | AKT1; PIK3R1; MET; HIF1A |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.783E-04 | 6.481E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.619E-03 | 6.035E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.119E-03 | 5.133E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.444E-03 | 5.702E-03 | AKT1; PIK3R1; NFKB1; TLR2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.525E-04 | 1.149E-03 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.825E-03 | 4.598E-03 | CA2; PLA2G1B; CD38; CFTR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.444E-03 | 5.702E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.463E-03 | 9.696E-03 | CAMK2B; AR; CDK1; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.438E-04 | 2.345E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.851E-03 | 8.562E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.327E-02 | 2.411E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 4.593E-03 | 9.754E-03 | AKT1; PIK3R1; CFTR; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.593E-03 | 9.754E-03 | GSK3B; CDK6; CDK1; TP53 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.920E-04 | 1.952E-03 | CSNK2A1; SRC; MET; IGF1R |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.725E-03 | 1.176E-02 | SYK; AKT1; PIK3R1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.021E-04 | 1.506E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.452E-02 | 2.565E-02 | CXCR1; THPO; FLT3; KDR; MET |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.916E-04 | 1.720E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 6.857E-03 | 1.336E-02 | GSK3B; AKT1; PIK3R1; PYGL |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.384E-03 | 1.410E-02 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 7.750E-03 | 1.450E-02 | SYK; CXCR1; AKT1; PIK3R1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.501E-02 | 2.627E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.741E-02 | 3.019E-02 | AKT1; PIK3R1; HIF1A |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.319E-02 | 2.411E-02 | CAMK2B; SRC; MMP2 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.398E-02 | 2.493E-02 | SYK; AKT1; PIK3R1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.206E-02 | 2.234E-02 | THPO; FLT3; CD38 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.327E-05 | 2.657E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 5.950E-03 | 1.209E-02 | SYK; AKT1; PIK3R1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.242E-03 | 1.397E-02 | PTGS2; NFKB1; TLR2 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 7.519E-03 | 1.421E-02 | CAMK2B; CA2; CFTR |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.448E-03 | 1.283E-02 | AKT1; PPARA; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.191E-03 | 9.210E-03 | AKT1; PIK3R1; HIF1A |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.024E-03 | 1.055E-02 | AKT1; PIK3R1; IGF1R |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 6.196E-03 | 1.246E-02 | CDK6; CDK1; TP53 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 5.246E-03 | 1.090E-02 | STAT6; NFKB1; TLR2 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 2.881E-02 | 4.736E-02 | MET; TLR2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.881E-02 | 4.736E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.963E-03 | 4.830E-03 | CYP2A6; CYP3A4; XDH |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.773E-02 | 4.639E-02 | PKM; PIK3R1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.727E-03 | 4.410E-03 | ABCC1; CFTR; ABCG2 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.460E-02 | 4.151E-02 | AKT1; PIK3R1 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.066E-02 | 3.517E-02 | FABP2; PLA2G1B |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.972E-02 | 3.388E-02 | PKM; GLO1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.368E-02 | 2.462E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.788E-03 | 1.336E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.519E-06 | 1.196E-05 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; PKM; SYK; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MMP9; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRNA7; PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | CHRNA7 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRNA7 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; NFKB1; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRNA7; CHRNA7; MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | CHRNA7 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CHRNA7; MAPT; PPARD |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRNA7; MAPT; ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; TLR2; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MMP9; NFKB1; PIM1; PARP1; CD38; TP53; ESR1; ESR1; KDR; APP |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; MMP12; PTGS1; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | CHRNA7; APP |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRNA7; CHRNA7; CHRNA7; DRD4 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRNA7; NPSR1; ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1; KDR; KDR |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; PTGS1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; IGF1R; IGF1R; AXL; KDR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; CHRNA7; MAOA; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; FLT3; MMP2; PTGS2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; TRPA1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |